AIDS Alert Archives – March 1, 2007
March 1, 2007
View Issues
-
Male circumcision in some nations may be the best available HIV prevention tool
Randomized clinical trials and other recent studies have confirmed earlier work showing a strong public health benefit for the use of male circumcision to prevent HIV infection in high-prevalence areas of the developing world. -
Aging and AIDS: Special series on older patients
Clinicians caring for older HIV patients increasingly need specific experience and training to deal with the treatment issues that are more commonly seen in this group. -
FDA Notifications: FDA approves lipidatrophy drug
On Dec. 22, 2006, the Food and Drug Administration (FDA) approved Radiesse, an injectable (under the skin) implant to restore or correct signs of facial lipidatrophy, or fat loss, in people with human immunodeficiency virus (HIV). -
FDA grants tentative approval of generic efavirenz
The Food and Drug Administration (FDA) has granted tentative approval for efavirenz capsules, 50 mg, 100 mg, and 200 mg, manufactured by Aurobindo Pharma Limited Inc., of Hyderabad, India. -
Update on the CNS Adverse Effects of Sustiva® (Efavirenz)
The US Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents recommends efavirenz (EFV) as part of the preferred non-nucleoside reverse transcriptase inhibitor-based regimen for HIV patients. -
Mentally ill patients with HIV suffer worse outcomes
Research shows that people with severe mental illness are at greater risk of becoming infected with HIV, their care is more costly when they are infected, and their health outcomes are worse than populations without mental illness.